Home » Stocks » DARE

Dare Bioscience, Inc. (DARE)

Stock Price: $1.40 USD -0.09 (-6.04%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Pre-market: $1.38 -0.02 (-1.43%) Apr 19, 4:00 AM
Market Cap 66.24M
Revenue (ttm) n/a
Net Income (ttm) -27.41M
Shares Out 47.31M
EPS (ttm) -0.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $1.40
Previous Close $1.49
Change ($) -0.09
Change (%) -6.04%
Day's Open 1.49
Day's Range 1.39 - 1.48
Day's Volume 579,078
52-Week Range 0.91 - 3.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Shares of Dare Bioscience (NASDAQ:DARE) decreased 2.4% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 4.76% year over year to ($0.22), which misse...

2 weeks ago - Benzinga

Conference Call and Webcast Today at 4:30 p.m. Eastern Time Conference Call and Webcast Today at 4:30 p.m. Eastern Time

2 weeks ago - GlobeNewsWire

Topline data readout targeted for year-end 2021 Topline data readout targeted for year-end 2021

3 weeks ago - GlobeNewsWire

SAN DIEGO, March 23, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p....

3 weeks ago - GlobeNewsWire

SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executiv...

1 month ago - GlobeNewsWire

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive...

1 month ago - GlobeNewsWire

SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive...

2 months ago - GlobeNewsWire

Shares of Daré Bioscience look poised to double between yesterday and today. DARE stock is an investment in women's health niches.

2 months ago - InvestorPlace

Sonoma Pharmaceuticals (NASDAQ: SNOA) shares are trading higher on Friday after the company announced a partnership with Gabriel Science for dental markets. Sonoma is engaged in identifying, developing ...

Other stocks mentioned: MDNAF, SNOA
4 months ago - Benzinga

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Shares of Dare Bioscience (NASDAQ:DARE) moved higher by 0.9% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 20.00% year over year to ($0.24),...

5 months ago - Benzinga

Conference Call Today at 4:30 p.m. Eastern Time Conference Call Today at 4:30 p.m. Eastern Time

5 months ago - GlobeNewsWire

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m...

5 months ago - GlobeNewsWire

SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Off...

6 months ago - GlobeNewsWire

Contraceptive Program Supported by approximately $20.5 Million in Grant Funding from the Bill & Melinda Gates Foundation to Date Contraceptive Program Supported by approximately $20.5 Million in Grant F...

6 months ago - GlobeNewsWire

Dare Bioscience: Preparing For The Upcoming Phase 3 Results

7 months ago - Seeking Alpha

SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, Daré’s President and CEO, will...

7 months ago - GlobeNewsWire

Agreement Intended to Facilitate Advancement of Daré’s Programs in a Capital Efficient Manner; Includes Economic Structures and Opportunities for Dedicated Staff Agreement Intended to Facilitate Advance...

7 months ago - GlobeNewsWire

SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it received a Notice of Award of a grant from the Eunice ...

7 months ago - GlobeNewsWire

Daré Bioscience, Inc.'s (DARE) CEO Sabrina Martucci Johnson on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Of...

8 months ago - GlobeNewsWire

SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p...

8 months ago - GlobeNewsWire

More than 45 million women in the U.S. are approaching or in menopause More than 45 million women in the U.S. are approaching or in menopause

8 months ago - GlobeNewsWire

Includes positive clinical findings from a postcoital test (PCT) human clinical study of Ovaprene®, an investigational hormone-free, monthly contraceptive

9 months ago - GlobeNewsWire

Topline data readout anticipated by the end of 2020 Topline data readout anticipated by the end of 2020

10 months ago - GlobeNewsWire

Contraceptive Program Supported by up to $20.5 Million in Grant Funding from the Bill & Melinda Gates Foundation Contraceptive Program Supported by up to $20.5 Million in Grant Funding from the Bill & M...

10 months ago - GlobeNewsWire

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Conference Call Today at 4:30 p.m. Eastern Time

11 months ago - GlobeNewsWire

SAN DIEGO, April 23, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it entered into a $15 million common stock purchase agreement...

11 months ago - GlobeNewsWire

SAN DIEGO, April 01, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it received a Notice of Award of $730,722 in a grant supporti...

1 year ago - GlobeNewsWire

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

DARE-BV1 demonstrated an 86% clinical cure rate in evaluable subjects at the test-of-cure visit after a single administration in an investigator-initiated proof of concept study, which is higher than th...

1 year ago - GlobeNewsWire

SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the presentation of positive findings from a previously repo...

1 year ago - GlobeNewsWire

SAN DIEGO, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, announced that it was notified by the Nasdaq Office of General Counsel that t...

1 year ago - GlobeNewsWire

As the biotechnology group is pushing near all-time highs, this past week played host to a huge number of biotech movers.

Other stocks mentioned: ADAP, AQST, BNTX, NKTR, NTGN
1 year ago - 24/7 Wall Street

Athenex Mixed Results, Boston Scientific Approval, And Other News: The Good, Bad, And Ugly Of Biopharma

Other stocks mentioned: ATNX, BSX, CFMS
1 year ago - Seeking Alpha

DARE-BV1 demonstrated an 86% clinical cure rate in evaluable subjects at the test-of-cure visit (Day 7-14) after a single administration in an investigator-initiated proof of concept study DARE-BV1 demo...

1 year ago - GlobeNewsWire

Sildenafil Cream, 3.6% has the Potential to Be the First FDA-Approved Product for FSAD Sildenafil Cream, 3.6% has the Potential to Be the First FDA-Approved Product for FSAD

1 year ago - GlobeNewsWire

Contraceptive Program Supported by up to $20.5 Million in Grant Funding from the Bill & Melinda Gates Foundation Contraceptive Program Supported by up to $20.5 Million in Grant Funding from the Bill & M...

1 year ago - GlobeNewsWire

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Contraceptive Program Supported by up to $20.5 Million in Grant Funding from the Bill & Melinda Gates Foundation Contraceptive Program Supported by up to $20.5 Million in Grant Funding from the Bill & M...

1 year ago - GlobeNewsWire

Sildenafil Cream, 3.6% produced statistically significant and clinically meaningful responses compared to placebo cream, further validating the potential for Sildenafil Cream, 3.6% to be an on-demand tr...

1 year ago - GlobeNewsWire

SAN DIEGO, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, its President and Chief Executive Officer...

1 year ago - GlobeNewsWire

SAN DIEGO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced a poster presentation at the American Society for Reproductive ...

1 year ago - GlobeNewsWire

SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that David Friend, Ph.D., its Chief Scientific Officer, will p...

1 year ago - GlobeNewsWire

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Daré Bioscience Inc. (DARE) CEO Sabrina Johnson on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Shares of Daré Bioscience Inc. rocketed 129% on very heavy volume toward a 13-month high in afternoon trade Monday.

2 years ago - Market Watch

Dare Bioscience Inc, a nanocap biotech company focused on developing therapies for women's health, is enjoying a moment in the spotlight thanks to positive results for its vaginally administered tamoxifen.

2 years ago - Benzinga

About DARE

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company intends to develop therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single application that completed Phase 3 clinical trials; Ovaprene, a hormone-free, monthly vaginal contraceptive; and ... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
DARE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is 5.00, which is an increase of 257.14% from the latest price.

Price Target
$5.00
(257.14% upside)
Analyst Consensus: Buy